1256359-22-4

Basic information

• Product Name: 1-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-1-one
• Synonyms: 1-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-1-one;4-(Propionyl)phenylboronic acid pinacol ester
• CAS NO: 1256359-22-4
• Molecular Formula: C₁₅H₂₁BO₃
• Molecular Weight: 260.13644
• Mol File: 1256359-22-4.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: Room temperature.
• CAS DataBase Reference: 1-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-1-one(1256359-22-4)
• EPA Substance Registry System: 1-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-1-one(1256359-22-4)

Safety Data

• Hazardous Substances Data: 1256359-22-4(Hazardous Substances Data)

Usage

General Description

1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-1-one is a chemical compound with a complex molecular structure. It consists of a phenyl ring with a boron-containing group attached to it, as well as a propanone group. The boron-containing group, specifically the dioxaborolan-2-yl group, gives the compound unique properties and potential applications in organic synthesis and material science. 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-1-one may be used as a building block in the synthesis of pharmaceuticals, agrochemicals, or optoelectronic materials, due to its boron-based functional group and aromatic ring. It has the potential to be an important intermediate in the production of various organic compounds and materials with diverse applications.

Upstream product

• 74-85-1 ethene 
• 180516-87-4 4-carboxyphenylboronic acid pinacol ester 
• 108-86-1 bromobenzene 
• 10342-83-3 4'-Bromopropiophenone 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1416164-53-8 1-(4-(2-chloro-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)-propan-1-one O-methyl oxime 
• 1416165-37-1 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-(1-(methoxyimino)-propyl)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1416165-36-0 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-propionylbenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 

Relevant articles and documents

1,2,4-Triazole-Based N-Heterocyclic Carbene Nickel Complexes - Synthesis and Catalytic Application

Four nickel complexes bearing 1,2,4-triazole-based N-heterocyclic carbene backbones and a cyclopentadienyl ligand were prepared from the corresponding 1,2,4-triazolium salts and nickelocene in tetrahydrofuran (THF) under reflux. The obtained complexes were fully characterized, including by X-ray diffraction analysis. They were then used as catalysts (5 mol-%) for the borylation of aryl bromide derivatives with bis(pinacolato)diboron in the presence of Cs2CO3 as the base in THF at 70 C for 20 h to form the corresponding borylated products in moderate yields. Four new nickel complexes bearing 1,2,4-triazole-based N-heterocyclic carbene backbones and a cyclopentadienyl ligand are prepared, fully characterized, and evaluated in the catalytic borylation of aryl bromides with bis(pinacolato)diboron.

Delta opiate receptor antagonist, application thereof and medicine composition

The invention discloses a compound with a structure shown as a general formula (I) (the general formula is shown in the description), a pharmaceutical salt, hydrate or metabolite formed through metabolism in any form, application of the compound with the

NOVEL SGLT INHIBITORS

The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula (I) and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).